nosis: a retrospective study of 90 tumors. *Am J Surg Pathol* 2002;26: 1605–1611.
25. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. *Cancer* 2002;95:420–429.
26. Girard N, Mornex F, Van Houtte P, et al. Thymoma: a focus on current therapeutic management. *J Thorac Oncol* 2009;4:119–126.
27. Tomiyama N, Muller NL, Ellis SJ, et al. Invasive and noninvasive thymoma: distinctive CT features. *J Comput Assist Tomogr* 2001;25: 388–393.
28a. Priola AM, Priola SM, Di Franco M, et al. Computed tomography and thymoma: distinctive findings in invasive and noninvasive thymoma and predictive features of recurrence. *Radiol Med* 2010;115:1–21.
28. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic review and practice guideline. *J Thorac Oncol* 2009;4: 911–919.
29. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. *Ann Thorac Surg* 2003;76:878–884; discussion 884–875.
30. Rena O, Papalia E, Oliaro A, et al. Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? *Eur J Cardiothorac Surg* 2007;31:109–113.
31. Singhal S, Shrager JB, Rosenthal DI, et al. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. *Ann Thorac Surg* 2003;76:1635–1641, discussion 1641–1632.
32. Wilkins EW Jr, Grillo HC, Scannell JG, et al. J. Maxwell Chamberlain Memorial Paper. Role of staging in prognosis and management of thymoma. *Ann Thorac Surg* 1991;51:888–892.
33. Myojin M, Choi NC, Wright CD, et al. Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study. *Int J Radiat Oncol Biol Phys* 2000;46:927–933.
34. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. *Crit Rev Oncol Hematol* 2003;45:55–75.
35. Boivin JF, Hutchison GB, Lubin JH, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. *Cancer* 1992;69: 1241–1247.
36. Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. *Am J Med* 1981;70:519–530.
37. Corn BW, Trock BJ, Goodman RL. Irradiation-related ischemic heart disease. *J Clin Oncol* 1990;8:741–750.
38. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. *J Clin Oncol* 1993;11:1208–1215.
39. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. *J Clin Oncol* 2007;25:43–49.
40. Jingu K, Kaneta T, Nemoto K, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. *Int J Radiat Oncol Biol Phys* 2006;66: 845–851.
41. Joensuu H. Acute myocardial infarction after heart irradiation in young patients with Hodgkin's disease. *Chest* 1989;95:388–390.
42. Joensuu H. Myocardial infarction after irradiation in Hodgkin's disease: a review. *Recent Results Cancer Res* 1993;130:157–173.
43. Paszat LF, Mackillop WJ, Groome PA, et al. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. *Int J Radiat Oncol Biol Phys* 1999;43:755–762.
44. Paszat LF, Vallis KA, Benk VM, et al. A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. *Radiother Oncol* 2007;82:294–300.
45. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. *Pediatric Blood Cancer* 2005;44:600–606.
46. Schimmel KJ, Richel DJ, van den Brink RB, et al. Cardiotoxicity of cytotoxic drugs. *Cancer Treat Rev* 2004;30:181–191.
47. Travis LB, Boice JD Jr, Travis WD. Second primary cancers after thymoma. *Int J Cancer* 2003;107:868–870.

Erratum

Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms: Erratum

In the article that appeared on page 1826 of the November 2010 issue, an author's academic degree was incorrect. The author's name should have appeared as Constance Johnson, PhD.

Reference:

Stewart, DJ, Johnson, CM, Lopez, A, Glisson, B, Rhee, J, Bekele, N. Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms. *J Thorac Oncol* 2010;5:1826–1834.

